Stocksigma LogoStocksigma Logo

AstraZeneca Pharma India Q2 Results and Key Leadership Appointments

AstraZeneca Pharma India reported Q2'26 revenue from operations of ₹7,291.0 mn, up 30.4% YoY from ₹5,590.9 mn, and net profit of ₹623.3 mn compared to

AstraZeneca Pharma India Q2 Results and Key Leadership Appointments

AstraZeneca Pharma India Ltd · Change in Management · 05 Nov 2026, 11:34 pm

AstraZeneca Pharma India Q2 Results and Key Leadership Appointments AstraZeneca Pharma India reported Q2'26 revenue from operations of ₹7,291.0 mn, up 30.4% YoY from ₹5,590.9 mn, and net profit of ₹623.3 mn compared to ₹542.2 mn in Q2'25, reflecting a 15.0% YoY rise. H1'26 revenue reached ₹14,118.9 mn with PAT at ₹1,002.6 mn. The board appointed Atul Tandon as CFO, Nitin Bindal as Director - Biopharmaceuticals Business Unit effective 9th Nov'26, and Kumaran Krishnan as Medical Director effective 1st Dec'26. Additionally, K. N. Iyer was appointed Non-Executive Independent Director for five years from 5th Nov'26.

Original exchange filing (PDF)

More announcements from AstraZeneca Pharma India Ltd

All AstraZeneca Pharma India Ltd announcements